Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
DIMA Biotechnology provides over 5,000 validated lead antibody molecules for approximately 400 drug targets. Their platforms enable rapid discovery and engineering of antibodies, including bispecifics, ADCs, and CAR-T candidates. The company does not develop its own therapeutics but empowers biopharma partners with advanced R&D tools to accelerate early-stage biologic drug discovery.
- Therapeutic areas
- Other
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateCAR-T cell therapy
- Industry
- Drug Discovery Services
02
Partnerships
Flexible partnership options with BioPharma companies for antibody-based drug discovery; specific partners not disclosed
Beyond the preview
Go deeper on DIMART.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIMART.